MPM Bioimpact LLC Grows Stock Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

MPM Bioimpact LLC boosted its stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 19.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 589,579 shares of the company's stock after purchasing an additional 96,856 shares during the quarter. Mirum Pharmaceuticals comprises about 3.5% of MPM Bioimpact LLC's investment portfolio, making the stock its 6th largest holding. MPM Bioimpact LLC owned about 1.23% of Mirum Pharmaceuticals worth $24,379,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of MIRM. Barclays PLC increased its holdings in Mirum Pharmaceuticals by 4.6% during the 3rd quarter. Barclays PLC now owns 245,918 shares of the company's stock worth $9,592,000 after purchasing an additional 10,824 shares in the last quarter. Hennion & Walsh Asset Management Inc. boosted its position in shares of Mirum Pharmaceuticals by 25.5% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 145,599 shares of the company's stock worth $6,021,000 after buying an additional 29,545 shares during the period. Avanza Fonder AB acquired a new position in shares of Mirum Pharmaceuticals during the fourth quarter worth about $189,000. Secure Asset Management LLC boosted its position in shares of Mirum Pharmaceuticals by 9.3% during the fourth quarter. Secure Asset Management LLC now owns 39,920 shares of the company's stock worth $1,651,000 after buying an additional 3,406 shares during the period. Finally, R Squared Ltd acquired a new position in shares of Mirum Pharmaceuticals during the fourth quarter worth about $69,000.

Insider Transactions at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 57,606 shares of the firm's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $44.35, for a total value of $2,554,826.10. Following the sale, the senior vice president now owns 4,841 shares of the company's stock, valued at approximately $214,698.35. This trade represents a 92.25% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Christopher Peetz sold 27,279 shares of the firm's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $44.21, for a total value of $1,206,004.59. Following the completion of the sale, the chief executive officer now directly owns 138,641 shares in the company, valued at approximately $6,129,318.61. This represents a 16.44% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 92,764 shares of company stock valued at $4,109,161. 14.36% of the stock is currently owned by corporate insiders.

Mirum Pharmaceuticals Stock Performance

Shares of Mirum Pharmaceuticals stock traded down $0.18 on Monday, hitting $44.84. The stock had a trading volume of 88,738 shares, compared to its average volume of 523,120. Mirum Pharmaceuticals, Inc. has a twelve month low of $23.83 and a twelve month high of $54.23. The business's 50 day moving average is $42.96 and its two-hundred day moving average is $44.51. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.33. The stock has a market cap of $2.22 billion, a price-to-earnings ratio of -22.20 and a beta of 0.95.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.30) earnings per share for the quarter, topping analysts' consensus estimates of ($0.35) by $0.05. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The company had revenue of $111.59 million during the quarter, compared to the consensus estimate of $98.47 million. During the same quarter last year, the firm earned ($0.54) earnings per share. The company's revenue was up 61.2% on a year-over-year basis. Analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

Analyst Ratings Changes

Several research analysts have recently weighed in on MIRM shares. JMP Securities upped their price objective on Mirum Pharmaceuticals from $74.00 to $76.00 and gave the stock a "market outperform" rating in a research report on Friday, May 9th. Raymond James reaffirmed a "strong-buy" rating on shares of Mirum Pharmaceuticals in a research report on Tuesday, May 13th. HC Wainwright reissued a "buy" rating and issued a $73.00 price objective on shares of Mirum Pharmaceuticals in a report on Monday. Finally, Robert W. Baird increased their price objective on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an "outperform" rating in a report on Thursday, February 27th. Ten analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Mirum Pharmaceuticals presently has a consensus rating of "Buy" and an average price target of $60.73.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.